Month: September 2023

-FDA Feedback on the Proposed Key Clinical and Regulatory Requirements Confirms CAP-1002’s Path Towards a Biologics License Application (BLA)- -Company On Track to Complete HOPE-3 Enrollment and Report Outcome from Interim Analysis in Q4 2023- -Conference Call and Webcast Today at 8:30 a.m. ET- SAN DIEGO, Sept. 29, 2023 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, today announced an update on the Company’s positive Type-B clinical meeting with the U.S. Food and Drug Administration (“FDA”) on the design and execution of HOPE-3, Capricor’s pivotal Phase 3 trial with lead asset CAP-1002 in treating Duchenne muscular dystrophy (“DMD”). Feedback from...

TORONTO, Sept. 29, 2023 (GLOBE NEWSWIRE) — APARTMENTLOVE INC. (CSE: APLV) (OTCQB: APMLF) (“ApartmentLove”, or the “Company”), a leading provider of online home, apartment and vacation rental marketing services to property managers, owners, renters and vacationers from around the world, is pleased to announce the signing of a share subscription agreement (the “Share Subscription Agreement”) between the Company and GEM Global Yield LLC SCS (“GGY”), a US$3.4 billion dollar alternative investment group with offices in New York, Paris and the Bahamas. The Share Subscription Agreement provides ApartmentLove the ability to draw multiple tranches (each, a “Draw Down”) of common shares (“Common Shares”) over the three-year term of the Share Subscription Agreement. Net proceeds received by the Company from the Share Subscription Agreement...

GSBR-1290 shown to be generally well-tolerated with no adverse event-related discontinuations in Phase 1b multiple ascending dose study Significant weight loss at 28 days supporting once-daily dosing Topline data from Phase 2a type 2 diabetes cohort expected in latter half of fourth quarter 2023; topline data from obesity cohort now expected in the first half 2024 Phase 2b studies in type 2 diabetes and obesity planned for initiation in 2024 Company to host conference call today, September 29 at 8:30 a.m. ET SAN FRANCISCO, Sept. 29, 2023 (GLOBE NEWSWIRE) — Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced positive results from the Phase 1b multiple ascending dose (MAD) study...

ATLANTA, Sept. 29, 2023 (GLOBE NEWSWIRE) — Chart Industries, Inc. (NYSE: GTLS) (“Chart”), a leading global engineering design and manufacturer of highly engineered equipment servicing multiple applications in clean energy and industrial gas markets, has scheduled a conference call for Friday, October 27, 2023 at 8:30 a.m. ET to discuss its third quarter 2023 financial results. Chart plans to issue its third quarter 2023 earnings release prior to market open on October 27th. Participants wishing to join the live Q&A session must dial-in with the following information: PARTICIPANT INFORMATION:Toll-Free – North America: (+1) 888 259 6580Toll North America and other locations: (+1) 416 764 8624Conference ID: 83938216 A live webcast and replay will be available on the Company’s investor relations website through the...

VANCOUVER, British Columbia, Sept. 29, 2023 (GLOBE NEWSWIRE) — Azucar Minerals Ltd. (“Azucar” or the “Company”) (TSX-V: AMZ; OTCQB: AXDDF) reports that, further to its press release of June 2, 2023, it has received notification from the First District Court of Veracruz (“First District Court”) that its Mexican subsidiary, Minera Alondra (“Alondra”), has been named in a lawsuit (“Amparo”) relating to twenty-four mineral concessions in Veracruz, Mexico (the “Concessions”), some of which are held by Alondra. The concessions owned by Alondra that are named in the Amparo cover the El Cobre project. The Amparo was filed in 2022 before the First District Court by thirty-three people from the municipalities of Actopan and Alto Lucero (the “Plaintiffs”) who claim that the Concessions affect their right to water and...

MALVERN, Pa., Sept. 29, 2023 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Arun Upadhyay, PhD, Ocugen’s Chief Scientific Officer, Head of Research, Development and Medical, will be among the featured speakers at the 4th Annual Gene Therapy for Ophthalmic Disorders conference, which is being held October 3-5, 2023 in Boston, Mass. Dr. Upadhyay will be speaking during two sessions: WorkshopTopic: Endpoints for Gene Therapy Clinical Trials in OphthalmologyDate: October 3, 2023 Time: 9 a.m. – noon ET Presentation Session: Fine-tuning the Design of First-in-Human Clinical StudiesTopic: Striking a Balance with Ascending Dose StudiesDate: October 5,...

WALNUT, Calif., Sept. 29, 2023 (GLOBE NEWSWIRE) — GigaCloud Technology Inc (Nasdaq: GCT) (“GigaCloud” or the “Company”), a pioneer of global end-to-end B2B ecommerce solutions for large parcel merchandise, today issued the following statement in response to claims made in a report by Culper Research, a short seller. The report lacks merit and contains numerous defamatory, selective, inaccurate, incomplete and misleading statements and speculations. The report demonstrates a fundamental lack of understanding of the Company’s business and financial condition. The Company is reviewing the claims and considering appropriate courses of action to protect the interests of all of its shareholders. As part of its commitment to transparency and compliance, the Company will make additional disclosures in due course consistent with the requirements...

TEL AVIV, Israel, Sept. 29, 2023 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare disease of the central nervous system, today announced the initiation of a pivotal clinical trial for its drug candidate, SCI-210, at the Soroka University Medical Center. SCI-210 is designed to help control symptoms of Autism Spectrum Disorder (“ASD”) and is an innovative proprietary combination of cannabidiol (“CBD”) and SciSparc’s Palmitoylethanolamide (PEA), the active ingredient of its proprietary CannAmide™. The study will evaluate the safety, tolerability, and efficacy of SCI-210, in comparison to CBD monotherapy in treating ASD. Designed as a randomized, double-blind,...

SAN DIEGO, Sept. 29, 2023 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, today announced that it has entered into definitive agreements with its commercial partner, Nippon Shinyaku, Co., Ltd. and funds associated with Highbridge Capital Management, LLC. for the issuance and sale of 4,935,621 shares of its common stock in a registered direct offering. Each share of common stock offered was sold with a warrant to purchase one share of common stock at an exercise price of $5.70 per share. Each warrant will be exercisable beginning six months after issuance and will expire seven years from the date of issuance. The combined offering price per share...

$300 million financing includes significant participation from a number of large healthcare dedicated institutional and mutual fund investors Net proceeds, along with existing cash, cash equivalents and short-term investments, are expected to extend cash runway through the end of 2026 SAN FRANCISCO, Sept. 29, 2023 (GLOBE NEWSWIRE) — Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced it has entered into a share purchase agreement for the sale of 21,617,295 ordinary shares and 2,401,920 newly designated non-voting ordinary shares (the equivalent of an aggregate of 8,006,405 American Depositary Shares (“ADSs”), each representing three ordinary shares) at $12.49 per share (based on...